The baseline characteristics of all patients and their clinical response after 12 and 24 weeks treatment with CZP
| Baseline characteristics | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Demographic characteristics | Disease characteristics | After 12 weeks CZP | After 24 weeks CZP | ||||||||||||||
| Age (years) | Gender (M/F) | Symptom duration (years) | Concomitant sDMARDs | Concomitant corticosteroids | Concomitant NSAIDs | CRP (mg/L) | ESR (mm/hour) | DAS 28 | ASDAS | CRP (mg/L) | ESR (mm/hour) | DAS28 | ASDAS | CRP (mg/L) | ESR (mm/hour) | DAS28 | ASDAS |
| RA (n=5) | |||||||||||||||||
| 68.8 | F | 38.7 | MTX 10 mg | Yes | No | 32 | 23 | 6.77 | – | 1.5 | 4 | 1.93 | – | 0.8 | 4 | 1.76 | – |
| 62.1 | F | 3.1 | MTX 10 mg | Yes | No | 8.6 | 11 | 6.33 | – | 13.3 | 13 | 4.79 | – | 9.1 | 16 | 3.29 | – |
| 57.2 | M | 1.5 | MTX 15 mg | Yes | No | 9.5 | 24 | 5.8 | – | 0.6 | 4 | 4.31 | – | 0.7 | 6 | 4.86 | – |
| 42.8 | F | 11.6 | MTX 12.5 mg | No | No | 3.9 | 15 | 4.62 | – | 2 | 12 | 2.16 | – | 3.7 | 11 | 2.24 | – |
| 50.3 | F | 10.8 | No | Yes | No | 0.6 | 8 | 3.89 | – | 0.6 | 10 | 2.31 | – | 0.6 | 10 | 3.87 | – |
| pSpA (n=6) | |||||||||||||||||
| 45.9 | M | 17.3 | MTX 15 mg | No | Yes | 51.9 | 67 | – | 4.78 | 2.8 | 6 | – | 1.56 | 0.6 | 2 | – | 0.99 |
| 36.8 | F | 0.9 | No | No | Yes | 3.4 | 5 | – | 4.16 | 1.6 | 4 | – | 3.87 | 1.6 | 4 | – | 3.87 |
| 55.4 | F | 39.9 | No | No | Yes | 0.1 | 6 | – | 2.18 | 0.6 | 3 | – | 1.02 | 0.6 | 7 | – | 2.98 |
| 44.8 | M | 4.2 | LEF | No | Yes | 28.2 | 57 | – | 3.89 | 0.6 | 5 | – | 0.46 | 0.7 | 5 | – | 0.93 |
| 25.1 | M | 1.2 | SSZ | No | Yes | 3.5 | 6 | – | 3.64 | 0.6 | 1 | – | 1.38 | 0.6 | 2 | – | 0.88 |
| 37.8 | M | 12.2 | No | No | No | 5.1 | 14 | – | 2.35 | 0.6 | 3 | – | 0.38 | 0.6 | 5 | – | 0.56 |
| nraxSpA (n=5) | |||||||||||||||||
| 26.7 | F | 4.4 | No | No | Yes | 9 | 8 | – | 3.05 | 2.7 | 3 | – | 1.65 | 0.7 | 2 | – | 1.61 |
| 42.4 | M | 5.2 | No | No | Yes | 2.5 | 5 | – | 2.94 | 0.7 | 2 | – | 2.22 | 0.6 | 1 | – | 2.91 |
| 45.8 | M | 19 | No | No | Yes | 4 | 11 | – | 2.67 | 0.6 | 3 | – | 0.73 | 0.6 | 3 | – | 0.68 |
| 44.5 | M | 3.5 | No | No | Yes | 6.3 | 4 | – | 3.38 | 3.9 | 5 | – | 1.58 | 4.2 | 7 | – | 3.25 |
| 35.2 | F | 19 | No | No | Yes | 4 | 5 | – | 4.07 | 6.2 | 8 | – | 2.59 | 5.7 | 11 | – | 2.18 |
| AS (n=4) | |||||||||||||||||
| 29.2 | M | 4.6 | No | No | Yes | 8 | 15 | – | 4.27 | 4.1 | 8 | – | 1.66 | 1.3 | 1 | – | 1.14 |
| 27.2 | M | 12.3 | No | No | Yes | 1.1 | 1 | – | 3.28 | 4.2 | 2 | – | 1.32 | 0.6 | 2 | – | 0.63 |
| 26.3 | M | 1.6 | No | No | Yes | 3 | 4 | – | 2.31 | 0.6 | 2 | – | 0.63 | 0.6 | 2 | – | 0.44 |
| 56.4 | M | 11.4 | No | No | Yes | 4.6 | 6 | – | 3.4 | 1.3 | 2 | – | 1.2 | 2.1 | 5 | – | 1.52 |
axSpA, axial spondyloarthritis; AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; CRP, C reactive protein; CZP, certolizumab pegol; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; LEF, leflunomide; M/F, male/female; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; pSpA, peripheral spondyloarthritis; RA, rheumatoid arthritis; sDMARDS, synthetic disease-modifying antirheumatic drugs; SSZ, sulfasalazine.